These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 34321571)

  • 1. Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis.
    Tsai WH; Chuang SM; Liu SC; Lee CC; Chien MN; Leung CH; Liu SJ; Shih HM
    Sci Rep; 2021 Jul; 11(1):15364. PubMed ID: 34321571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Class effects of SGLT2 inhibitors on cardiorenal outcomes.
    Kluger AY; Tecson KM; Lee AY; Lerma EV; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
    Cardiovasc Diabetol; 2019 Aug; 18(1):99. PubMed ID: 31382965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety outcomes of sodium-glucose cotransporter 2 inhibitors in patients with different renal function: A systematic review and meta-analysis.
    Bai Y; Jin J; Zhou W; Zhang S; Xu J
    Nutr Metab Cardiovasc Dis; 2021 May; 31(5):1365-1374. PubMed ID: 33812735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential Analysis.
    Zhang XL; Zhu QQ; Chen YH; Li XL; Chen F; Huang JA; Xu B
    J Am Heart Assoc; 2018 Jan; 7(2):. PubMed ID: 29353233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and meta-analysis.
    Guo M; Ding J; Li J; Wang J; Zhang T; Liu C; Huang W; Long Y; Gao C; Xu Y
    Diabetes Obes Metab; 2018 Aug; 20(8):1977-1982. PubMed ID: 29573118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis.
    Usman MS; Siddiqi TJ; Memon MM; Khan MS; Rawasia WF; Talha Ayub M; Sreenivasan J; Golzar Y
    Eur J Prev Cardiol; 2018 Mar; 25(5):495-502. PubMed ID: 29372664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Liu J; Li L; Li S; Jia P; Deng K; Chen W; Sun X
    Sci Rep; 2017 Jun; 7(1):2824. PubMed ID: 28588220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis.
    Castellana M; Procino F; Sardone R; Trimboli P; Giannelli G
    Cardiovasc Diabetol; 2020 Jun; 19(1):87. PubMed ID: 32534590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-Glucose Cotransporter-2 Inhibitors and Protection Against stroke in Patients with type 2 Diabetes and Impaired Renal Function: A Systematic Review and Meta-Analysis.
    Barkas F; Ntekouan SF; Liberopoulos E; Filippatos T; Milionis H
    J Stroke Cerebrovasc Dis; 2021 May; 30(5):105708. PubMed ID: 33714073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis.
    Salah HM; Al'Aref SJ; Khan MS; Al-Hawwas M; Vallurupalli S; Mehta JL; Mounsey JP; Greene SJ; McGuire DK; Lopes RD; Fudim M
    Cardiovasc Diabetol; 2022 Feb; 21(1):20. PubMed ID: 35123480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis.
    Zhou Z; Jardine MJ; Li Q; Neuen BL; Cannon CP; de Zeeuw D; Edwards R; Levin A; Mahaffey KW; Perkovic V; Neal B; Lindley RI;
    Stroke; 2021 May; 52(5):1545-1556. PubMed ID: 33874750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis.
    Savarese G; D'Amore C; Federici M; De Martino F; Dellegrottaglie S; Marciano C; Ferrazzano F; Losco T; Lund LH; Trimarco B; Rosano GM; Perrone-Filardi P
    Int J Cardiol; 2016 Oct; 220():595-601. PubMed ID: 27390996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
    Wu JH; Foote C; Blomster J; Toyama T; Perkovic V; Sundström J; Neal B
    Lancet Diabetes Endocrinol; 2016 May; 4(5):411-9. PubMed ID: 27009625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kidney outcomes using a sustained ≥40% decline in eGFR: A meta-analysis of SGLT2 inhibitor trials.
    Cherney DZI; Dagogo-Jack S; McGuire DK; Cosentino F; Pratley R; Shih WJ; Frederich R; Maldonado M; Liu J; Wang S; Cannon CP;
    Clin Cardiol; 2021 Aug; 44(8):1139-1143. PubMed ID: 34129237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.
    Neuen BL; Young T; Heerspink HJL; Neal B; Perkovic V; Billot L; Mahaffey KW; Charytan DM; Wheeler DC; Arnott C; Bompoint S; Levin A; Jardine MJ
    Lancet Diabetes Endocrinol; 2019 Nov; 7(11):845-854. PubMed ID: 31495651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models.
    Andreadou I; Bell RM; Bøtker HE; Zuurbier CJ
    Biochim Biophys Acta Mol Basis Dis; 2020 Jul; 1866(7):165770. PubMed ID: 32194159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of sodium glucose cotransporter 2 inhibitors on risk of dyslipidemia among patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Li D; Wu T; Wang T; Wei H; Wang A; Tang H; Song Y
    Pharmacoepidemiol Drug Saf; 2020 May; 29(5):582-590. PubMed ID: 32124527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-glucose co-transporter-2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials.
    Okunrintemi V; Mishriky BM; Powell JR; Cummings DM
    Diabetes Obes Metab; 2021 Jan; 23(1):276-280. PubMed ID: 33001548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
    Gebrie D; Getnet D; Manyazewal T
    Sci Rep; 2021 Jan; 11(1):137. PubMed ID: 33420333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Liu J; Li L; Li S; Wang Y; Qin X; Deng K; Liu Y; Zou K; Sun X
    Diabetes Obes Metab; 2020 Sep; 22(9):1619-1627. PubMed ID: 32364674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.